SCHAUMBURG, Ill.--(BUSINESS WIRE)--APP Pharmaceuticals, Inc. (Nasdaq: APPX) is communicating in a letter to its customers that the company continues to work closely with the U.S. Food and Drug Administration (FDA) to ensure that an uninterrupted and safe supply of heparin of the highest quality is available for U.S. patients.
